Serum Proteomic Analysis of the Patients Suffering with End Stage Renal Disease and Left Ventricular Hypertrophy

Background: There is high risk of left ventricular hypertrophy (LVH) in hemodialysis patients and attention is required to address this problem. Till date most of the proteomics studies in Chronic Kidney Disease (CKD) have been carried out in urine samples and have revealed some important protein biomarkers. Objective: The current study was undertaken to evaluate the serum proteomic profile in hemodialysis patients with LVH. Methods: The study comprised of 12 hemodialysis patients with evidence of LVH and 12 normal healthy individuals. The serum samples pooled from cases and normal healthy individuals were subjected to 2D-DIGE followed by gel analysis. Fifteen spots were selected based on folds of increase or decrease and uniqueness of the protein spot for further mass spectrum (MS) analysis. The 3D structures of proteins were predicted using Prime from Schrodinger software. From the MS data, the 1D structure of protein was assessed through which 2D structure and 3D structure were predicted using in silico tools. Protein structure validation was done using PROCHECK and ERRAT and further protein interaction was studied using STRING analysis. Results: The results data suggest that plasma inflammatory proteins (like Monoclonal antibody CH89 heavy chain (partial), Immunoglobin heavy chain variable region, IgM heavy chain VH1 region precursor), nuclear related proteins (such as zinc finger protein 224, lethal malignant brain tumor like protein, mitotic check point) were differentially expressed. Conclusion: The assessment of serum proteomics in hemodialysis with LVH provides an altered protein pattern, which may serve as a potential biomarker for monitoring the course of the disease.